Adagene Reports Promising ADG126 Study Results at ASCO, Stock Trading Volume at 26,496 with a Technical Sentiment Signal of Sell.

Adagene reported promising results from its Phase 1b/2 study of ADG126 in combination with KEYTRUDA for advanced microsatellite stable colorectal cancer, with a 29% overall response rate in the 20 mg/kg cohort. The study showed reduced treatment-related toxicities and durable responses, supporting further clinical development discussions with regulatory bodies. Analysts rate ADAG stock as a Hold with a $3.50 price target.

Adagene Inc. (NASDAQ: ADAG) recently announced updated data from its Phase 1b/2 study of ADG126 in combination with KEYTRUDA (pembrolizumab) for the treatment of advanced microsatellite stable colorectal cancer (MSS CRC). The study, presented at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrated a 29% overall response rate (ORR) in the 20 mg/kg cohort, with all six responders remaining on treatment and four continuing beyond 40 weeks. This marks a significant advancement in treating MSS CRC, a notoriously difficult-to-treat subtype.

The study also reported a median overall survival (OS) of 19.4 months in the 10 mg/kg cohorts, comparing favorably with current standards of care. Notably, the 20 mg/kg Q6W dosing regimen showed equivalent efficacy with reduced toxicity compared to other regimens. The study's safety profile was promising, with less than 20% Grade 3 adverse events, indicating a more manageable toxicity profile than traditional CTLA-4 inhibitors.

Adagene plans to discuss the dosing regimen with regulatory bodies for the next phase of clinical development. Analysts currently rate ADAG stock as a Hold with a $3.50 price target [1].

References:
[1] https://www.stocktitan.net/news/ADAG/adagene-announces-updated-data-from-phase-1b-2-study-of-muzastotug-cgmiuaoccfst.html